SRX gross margins 84.3%

A key take from the directors report is that gross margins increased due to:
Improved efficiencies due to higher manufacturing volumes
A full year without a contract manufacturer
And a price increase in the USA region

A very key aspect of the SRX business which has enormous potential to be leveraged over coming decades is this:

They are not necessarily building just a liver cancer treatment business...they are building a global highly efficient distribution business. Scope for growing the business in other areas is significant.